Connection

ERNEST HAWK to Cyclooxygenase 2 Inhibitors

This is a "connection" page, showing publications ERNEST HAWK has written about Cyclooxygenase 2 Inhibitors.
Connection Strength

1.367
  1. An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Gut. 2016 Feb; 65(2):286-95.
    View in: PubMed
    Score: 0.461
  2. The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo. Clin Ther. 2012 Mar; 34(3):569-79.
    View in: PubMed
    Score: 0.093
  3. C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer Prev Res (Phila). 2011 Aug; 4(8):1172-80.
    View in: PubMed
    Score: 0.090
  4. Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res (Phila). 2011 Nov; 4(11):1728-35.
    View in: PubMed
    Score: 0.089
  5. The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol. 2010 Jun; 105(6):1437-43.
    View in: PubMed
    Score: 0.081
  6. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila). 2009 Apr; 2(4):310-21.
    View in: PubMed
    Score: 0.076
  7. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008 Apr 22; 117(16):2104-13.
    View in: PubMed
    Score: 0.071
  8. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006 Aug 31; 355(9):873-84.
    View in: PubMed
    Score: 0.064
  9. Cyclooxygenase inhibition in cancer prevention and treatment. Expert Opin Pharmacother. 2003 Dec; 4(12):2193-204.
    View in: PubMed
    Score: 0.053
  10. Development of COX inhibitors in cancer prevention and therapy. Am J Clin Oncol. 2003 Aug; 26(4):S48-57.
    View in: PubMed
    Score: 0.051
  11. Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trials. Prog Exp Tumor Res. 2003; 37:210-42.
    View in: PubMed
    Score: 0.049
  12. The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Des. 2002; 8(12):1035-62.
    View in: PubMed
    Score: 0.046
  13. The future of colon cancer prevention. Ann N Y Acad Sci. 2001 Dec; 952:88-108.
    View in: PubMed
    Score: 0.046
  14. Strategy for prevention of cancers of the esophagus. Ann N Y Acad Sci. 2014 Sep; 1325:108-26.
    View in: PubMed
    Score: 0.028
  15. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013 Aug 31; 382(9894):769-79.
    View in: PubMed
    Score: 0.025
  16. The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma. Cancer Prev Res (Phila). 2012 Jan; 5(1):61-72.
    View in: PubMed
    Score: 0.023
  17. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000 Jun 29; 342(26):1946-52.
    View in: PubMed
    Score: 0.010
  18. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res. 2000 Apr 01; 60(7):1864-70.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.